Aclarion ACON 深 沪
等待开盘 08-27 09:30:00 美东时间
2.39
-0.100
-4.02%
华盛通- 最 高2.46
- 今 开2.46
- 成交量 10.36万股
- 最 低 2.32
- 昨 收 2.49
- 总市值 688.89万
- 52周最高 12.03
- 市盈率 静 --
- 换手率 3.59%
- 52周最低 1.95
- 委 比 -62.41%
- 总股本 288.24万
- 历史最高 586116.00
- 量 比 1.18
- 振 幅 5.62%
- 历史最低 1.95
- 每 手 1
- 风险率 2.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aclarion Announces University Of Arizona College Of Medicine - Phoenix As New Clinical Site In Its CLARITY Trial
University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation Ten sites now actively enrolling in CLARITY study, a prospective, randomized cli...
08-20 19:01
Aclarion Says USPTO Issues Notice Of Allowance For U.S. Patent Application Titled Multi-Voxel Prescription For Lumbar Disc Evaluation
Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers Extends Aclarion's IP protection to over 65 issued and...
08-12 19:04
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
Aclarion, Inc. announced the issuance of a U.S. patent titled "Multi-Voxel Prescription for Lumbar Disc Evaluation," enhancing their Nociscan workflow. The patent addresses challenges in MR Spectroscopy data capture, improving scan efficiency, consistency, and reproducibility across imaging centers. It complements Aclarion's existing portfolio of over 65 issued and pending patents globally, supporting their mission to help physicians identify chr...
08-12 11:00
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
Aclarion, Inc. reported strong momentum in the first half of 2026, with a 141% year-over-year scan volume growth and 71% sequential growth, driven by increased physician engagement and commercial execution. The company expanded Nociscan utilization in the U.S. and U.K., secured reimbursement in the U.K., and partnered with PRIA Healthcare to establish payer coverage in the U.S. Progress continued toward the CLARITY trial readout, and intellectual...
07-29 11:00
Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice
Aclarion, Inc. presented two abstracts at the ASPN Annual Meeting highlighting Nociscan's clinical utility in chronic low back pain management. The first abstract demonstrated the successful integration of MRS technology into clinical workflows for identifying symptomatic discs, while the second presented a case study where Nociscan guided basivertebral nerve ablation in a patient without classic Modic changes, achieving 95% pain relief. Nociscan...
07-21 11:00
Aclarion Announces Texas Spine Care Center As New Clinical Site In Chronic Low bAck pain Randomized Independent Trial studY Trial
Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understanding the exact source of a patient's pain before recommending treatment CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chr...
07-07 19:06
Aclarion Announces Texas Spine Care Center as New CLARITY Site
Texas Spine Care Center has joined the CLARITY trial, a clinical study aiming to demonstrate the effectiveness of Nociscan in improving surgical outcomes for chronic low back pain. Nociscan uses MR Spectroscopy and AI to identify pain sources, offering objective biomarker insights. The trial, led by Aclarion, Inc., involves multiple high-volume sites and evaluates Nociscan's impact on pain reduction over 12 months. With a focus on precise, indivi...
07-07 11:00
Aclarion Launches Market Access Program In Partnership With PRIA Healthcare
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain.Program aims to follow successful reimbursement wins in the UK that are translating
06-09 19:04
Aclarion Board Reviews Echo Lake's Unsolicited Public Proposal And Unanimously Determined To Reject It
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help
06-08 19:13
美股大行评级 | Susquehanna上调美光目标价从600美元升至1750美元；戴尔、MongoDB、网泰信息存储、Nextpower、Okta等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从7美元升至7.5美元；Susquehanna：维持美光科技"积极"评级，目标价从600美元升至1750美元
06-01 14:11
